Please assess the completion status of the following clinical trial:

Trial Title: Natural Killer (NK) Cell Transplantation for AML

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with AML that is in complete remission, is relapsed or refractory, or with increasing minimal residual disease.~* Participants in complete remission must have recovered from toxicity of previous therapy and have evidence of bone marrow recovery~* Participants who had prior stem cell transplant (SCT) must have no evidence of GVHD and 60 or more days have elapsed since the SCT.~Exclusion Criteria:~* Participants who are pregnant~* Participants with inadequate renal, liver, or pulmonary functions

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Stratum 1 (Type: EXPERIMENTAL): Stratum 1 (AML in complete remission)~Cyclophosphamide 60 mg/kg IV Day -7 Fludarabine 25 mg/m2/day IV Days -6 through -2 Donor pheresis Day -1 Start IL-2 on Day -1, then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0
- Stratum 2 (Type: EXPERIMENTAL): Stratum 2 (AML that is refractory or relapsed or AML with increasing minimal residual disease)~Clofarabine 40 mg/m2 IV, days -6 through -2 Etoposide 100 mg/m2 IV, days -6 through -2 Cyclophosphamide 400 mg/m2 IV, days -6 through 02 Donor pheresis Day -1 Start IL-2 Day -1, and then 3 times per week x 2 weeks NK Cell purification and infusion on Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).